BusinessBioSig Technologies Announces Results of Independent Product Assessment Study for PURE EP SystemBy Nasdaq OMXOct 26, 2017, 12:01 PM UTC
BusinessBioSig Technologies Adds Role of Manufacturing Project Leader as Company Continues to Advance Towards CommercializationBy Nasdaq OMXOct 24, 2017, 12:00 PM UTC
BusinessBioSig Technologies Advances Towards Commercialization into the Global Electrophysiology Market Estimated to Reach $8.2 Billion by 2022By Nasdaq OMXOct 19, 2017, 12:00 PM UTC
BusinessBioSig Technologies to Present at the Dawson James Small Cap Growth ConferenceBy Nasdaq OMXOct 13, 2017, 12:00 PM UTC
BusinessTelemedicine Technology Joint Venture Announced Between Cytta Corp and Cardiocomm SolutionsBy Nasdaq OMXOct 12, 2017, 11:30 AM UTC
BusinessBioSig Technologies Welcomes Joseph W. Rafferty as Chief Commercialization OfficerBy Nasdaq OMXOct 11, 2017, 12:00 PM UTC
BusinessARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical TrialBy Nasdaq OMXAug 16, 2017, 12:30 PM UTC
BusinessARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim AnalysisBy Nasdaq OMXAug 9, 2017, 8:30 PM UTC
